Aventis/Novartis update
This article was originally published in The Tan Sheet
Executive Summary
No formal negotiations have taken place on price tag for France's number one pharmaceutical company, Aventis CEO Igor Landau says in an April 2 conference call. Landau said the firm has "close to two months" to accelerate price negotiations if Novartis maintains interest; Aventis will propose resolutions including a 2003 dividend to shareholders at a May 19 annual meeting. If the merger is successful, Novartis likely would spin off non-core pharmaceutical and consumer brands into a separate entity (1"The Tan Sheet" March 29, 2004, p. 5)...You may also be interested in...
Novartis/Aventis Consumer Products Combo Would Be Divested
Novartis would spin-off a combination of its consumer health products and Aventis' older drugs if the two companies were to merge
Health And Wellness Trademark Review 14 January, 2020
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention
Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: